Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-cash Items (2018 - 2025)

Historic Non-cash Items for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Q2 2025 value amounting to $81.3 million.

  • Crinetics Pharmaceuticals' Non-cash Items fell 7187.51% to $81.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $81.3 million, marking a year-over-year decrease of 7187.51%. This contributed to the annual value of $6.5 million for FY2024, which is 2326.86% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Non-cash Items stood at $81.3 million for Q2 2025, which was down 7187.51% from $7.0 million recorded in Q1 2025.
  • Crinetics Pharmaceuticals' Non-cash Items' 5-year high stood at $3.0 billion during Q4 2021, with a 5-year trough of $2834.0 in Q3 2021.
  • Over the past 5 years, Crinetics Pharmaceuticals' median Non-cash Items value was $6.7 million (recorded in 2024), while the average stood at $216.5 million.
  • The largest annual percentage gain for Crinetics Pharmaceuticals' Non-cash Items in the last 5 years was 245075995.09% (2021), contrasted with its biggest fall of 9998.97% (2021).
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Non-cash Items stood at $3.0 billion in 2021, then tumbled by 99.23% to $23.1 million in 2022, then crashed by 77.3% to $5.3 million in 2023, then grew by 23.27% to $6.5 million in 2024, then soared by 1154.48% to $81.3 million in 2025.
  • Its Non-cash Items was $81.3 million in Q2 2025, compared to $7.0 million in Q1 2025 and $6.5 million in Q4 2024.